Zentalis

Zentalis : Discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Middle Atlantic
Clinical Stage
Phase l or ll
Disease Space
Oncology
Listing
Public, USA
Market Cap
1B +
Website:
Profiles:
Address:
530 Seventh Avenue, Ste 2201
Corner of 39 St
New York, NY 10018
United States

Company Participants at 2nd Solebury Trout Virtual Global Healthcare Conference Series

Anthony Sun
Zentalis, CEO
Anthony has played an active role across the life science industry since 2002 and currently serves as Chief Executive Officer for Zentalis Pharmaceuticals. From 2002 until 2015, he was at Aisling Capital and Perseus-Soros Biopharmaceutical Fund, private equity firms dedicated to the life sciences, during which he held multiple positions most recently as Partner. Dr. Sun holds a BS in Electrical Engineering from Cornell University, an MD from Temple University School of Medicine, an MBA from The Wharton School at the University of Pennsylvania. He trained in internal medicine at the Hospital of the University of Pennsylvania and was board certified in internal medicine.

Lead Programs

ZN-c5: Oral SERD

oral selective estrogen receptor degrader (SERD)

Indication Phase
Breast Cancer 1/2

ZN-c3: WEE1

oral inhibitor of WEE1

Indication Phase
Solid Tumors 1/2

ZN-d5: BCL-2

oral selective inhibitor of B-cell lymphoma 2 (BCL-2)

Indication Phase
Hematologic Malignancies IND

ZN-e4: EGFR

oral, small molecule inhibitor of mutant epidermal growth factor receptor (EGFR)

Indication Phase
NSCLC 1/2

Top 10 Holders of Zentalis Pharmaceuticals, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Viking Global Investors LP 10.99 3,943,284 170.43 Stakes 12/1/20
Matrix Capital Management Co. LP 10.65 3,821,739 165.18 13F 9/30/20
Fidelity Management & Research Co. LLC 7.95 2,850,720 123.21 13F 9/30/20
Tybourne Capital Management (HK) Ltd. 7.43 2,664,409 115.16 13F 9/30/20
Redmile Group LLC 6.78 2,432,408 105.13 13F 9/30/20
The Vanguard Group, Inc. 6.52 2,340,316 101.15 Funds 12/31/20
Citadel Advisors LLC 5.24 2,129,964 92.06 Stakes 4/3/20
Citadel LP 4.71 1,689,634 73.03 13F 9/30/20
PRIMECAP Management Co. 3.85 1,382,750 59.76 13F 9/30/20
Vanguard Group, Inc. (Subfiler) 3.09 1,109,753 47.96 13F 9/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.